27 September, 2021 by The TZ Newswire Staff Comments Off on Fastsættelse af kuponrente
Fastsættelse af kuponrente
Til Nasdaq Copenhagen A/S 27. september 2021
Meddelelse nr. 91/2021
Fastsættelse af kuponrente
Renten for Jyske Realkredits:
Serie 454.B.38 med ISIN: DK0009361628 er fra og med 1. oktober 2021 til og med 31. marts 2022 fastsat til 0,72 % p.a.
Serie 154.B.38 med ISIN: DK0009361701 er fra og med 1. oktober 2021 til og med 31. marts 2022 fastsat til 0,72 % p.a.
27 September, 2021 by The TZ Newswire Staff Comments Off on Fixing of Coupon Interest Rate
Fixing of Coupon Interest Rate
To Nasdaq Copenhagen A/S 27 September 2021
Announcement no. 91/2021
Fixing of Coupon Interest Rate
Interest rate for Jyske Realkredit’s:
Series 454.B.38 with ISIN DK0009361628 has per 1 October 2021 and until and including 31 March 2022 been set at 0.72 % p.a.
Series 154.B.38 with ISIN DK0009361701 has per 1 October 2021 and until and including 31 March 2022 been set at 0.72 % p.a.
27 September, 2021 by The TZ Newswire Staff Comments Off on DSM: Net Asset Value(s)
DSM: Net Asset Value(s)
27 September, 2021 by The TZ Newswire Staff Comments Off on HIGHCO : transactions sur Actions propres du 20/09/21 au 24/09/21
HIGHCO : transactions sur Actions propres du 20/09/21 au 24/09/21
Déclaration des transactions sur actions propres
Réalisées du 20 au 24 septembre 2021
27 September, 2021 by The TZ Newswire Staff Comments Off on Cardano (ADA) developers can now leverage Chainlink for better smart contracts
Cardano (ADA) developers can now leverage Chainlink for better smart contracts
Cardano is scaling up its decentralized finance (DeFi) smart contract development with a new partnership with Chainlink who will be providing the upgraded crypto asset with its oracle integration services for developers on the ecosystem.
This was announced by the parent company, InputOutput (IOHK), of the blockchain project at the Cardano Summit 2021.
27 September, 2021 by The TZ Newswire Staff Comments Off on ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis
ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis
– Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile
27 September, 2021 by The TZ Newswire Staff Comments Off on Genetron Health and IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline
Genetron Health and IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline
BEIJING, Sept. 27, 2021 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced a partnership with IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics.